These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 4374762)
21. A review of NMDA receptors and the phencyclidine model of schizophrenia. Thornberg SA; Saklad SR Pharmacotherapy; 1996; 16(1):82-93. PubMed ID: 8700797 [TBL] [Abstract][Full Text] [Related]
23. Brain-derived neurotrophic factor in schizophrenia and its relation with dopamine. Guillin O; Demily C; Thibaut F Int Rev Neurobiol; 2007; 78():377-95. PubMed ID: 17349867 [TBL] [Abstract][Full Text] [Related]
24. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. Javitt DC Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858 [TBL] [Abstract][Full Text] [Related]
25. [Clinical aspects and follow-up of dopamine-induced psychoses in continuous dopaminergic therapy and their implications for the dopamine hypothesis of schizophrenic symptoms]. Heinz A; Przuntek H; Winterer G; Pietzcker A Nervenarzt; 1995 Sep; 66(9):662-9. PubMed ID: 7477603 [TBL] [Abstract][Full Text] [Related]
26. [Old and new thought concepts on the biochemical principles of psychopharmcotherapy]. Wunderlich H; Wunderlich HP Samml Zwangl Abh Geb Psychiatr Neurol; 1982; 50():61-80. PubMed ID: 6130615 [No Abstract] [Full Text] [Related]
28. The administration of methionine to chronic schizophrenic patients: a review of ten studies. Cohen SM; Nichols A; Wyatt R; Pollin W Biol Psychiatry; 1974 Apr; 8(2):209-25. PubMed ID: 4601948 [No Abstract] [Full Text] [Related]
29. Role of central glutamatergic neurotransmission in the pathogenesis of psychiatric and behavioral disorders. Wang SJ; Yang TT Drug News Perspect; 2005 Nov; 18(9):561-6. PubMed ID: 16421629 [TBL] [Abstract][Full Text] [Related]
30. Emotions and the autonomic nervous system. Wolf S Arch Intern Med; 1970 Dec; 126(6):1024-30. PubMed ID: 4394904 [No Abstract] [Full Text] [Related]
31. [Psychochemistry, from an historical and biological point of view]. Vondrácek V Psychiatr Neurol Med Psychol (Leipz); 1971 May; 23(5):257-66. PubMed ID: 4940121 [No Abstract] [Full Text] [Related]
32. [Problem of neuronal reception and the dopamine hypothesis of schizophrenia]. Lideman RR; Zlobina GP; Mukhin AG Zh Nevropatol Psikhiatr Im S S Korsakova; 1980; 80(5):762-9. PubMed ID: 6106337 [No Abstract] [Full Text] [Related]
33. A dopaminergic-cholinergic mechanism in production of psychotic symptoms. Friedhoff AJ; Alpert M Biol Psychiatry; 1973 Apr; 6(2):165-9. PubMed ID: 4709131 [No Abstract] [Full Text] [Related]
34. New directions in clinical psychopharmacology. Cardoni AA Conn Med; 1997 Sep; 61(9):587-95. PubMed ID: 9334514 [TBL] [Abstract][Full Text] [Related]
35. Therapeutic standards in psychopharmacology and medical decision-making. Linden M Pharmacopsychiatry; 1994 Jul; 27 Suppl 1():41-5. PubMed ID: 7984701 [TBL] [Abstract][Full Text] [Related]
36. Neuropharmacology of psychotomimetic drugs. Murphree HB J Med Soc N J; 1968 Oct; 65(10):537-42. PubMed ID: 5273165 [No Abstract] [Full Text] [Related]
38. Medicine. What are the right targets for psychopharmacology? Hyman SE; Fenton WS Science; 2003 Jan; 299(5605):350-1. PubMed ID: 12532001 [No Abstract] [Full Text] [Related]
39. [Possibilities for early recognition and prevention of psychoneurotic and psychosomatic diseases during an internist's consultations]. Wesiack W Psychother Med Psychol (Stuttg); 1977 Jan; 27(1):31-4. PubMed ID: 840996 [No Abstract] [Full Text] [Related]
40. [Usefulness and hazards of psychopharmacological agents]. Marino A Clin Ter; 1974 Oct; 71(1):3-12. PubMed ID: 4426175 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]